RET and thyroid cancer: In the case of selpercatinib, FDA accelerated approval was based on a cohort of 19 patients with RET-fusion-positive thyroid cancer (including three with poorly differentiated and two with anaplastic tumors), 15 of whom responding to treatment (53).